

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/937,840
				Filing Date	April 21, 2000 (Int'l)
				First Named Inventor	Patrick SOON-SHIONG
				Art Unit	1614
				Examiner Name	J. Anderson
Sheet	1	of	3	Attorney Docket Number	420052000200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JDA/	1.	US-2003/0105156-A1	06-05-2003	Palepu et al.	
	2.	US-2003/0199425-A1	10-23-2003	Desai et al.	
	3.	US-2004/0248781-A1	12-09-2004	Kerbel	
	4.	US-2005/0004002-A1	01-06-2005	Desai et al.	
	5.	US-2006/0073175-A1	04-06-2006	Soon-Shiong et al.	
	6.	US-2006/0083782-A1	04-20-2006	Desai et al.	
	7.	US-2006/0241170-A1	10-26-2006	Soon-Shiong et al.	
	8.	US-2006/0257326-A1	11-16-2006	Desai et al.	
	9.	US-2006/0263434-A1	11-23-2006	Desai et al.	
	10.	US-2007/0082838-A1	04-12-2007	De et al.	
	11.	US-2007/0087022-A1	04-19-2007	Desai et al.	
	12.	US-2007/0092563-A1	04-26-2007	Desai et al.	
	13.	US-2007/0093547-A1	04-26-2007	Desai et al.	
	14.	US-2007/0117862-A1	05-24-2007	Desai et al.	
	15.	US-2007/0117863-A1	05-24-2007	Desai et al.	
	16.	US-2007/0116761-A1	05-24-2007	Desai et al.	
	17.	US-2007/0116774-A1	05-24-2007	Desai et al.	
	18.	US-2007/0117744-A1	05-24-2007	Desai et al.	
	19.	US-2007/0122465-A1	05-31-2007	Desai et al.	
	20.	US-2007/0122468-A1	05-31-2007	Desai et al.	
	21.	US-2007/0128290-A1	06-07-2007	Desai et al.	
	22.	US-2007/0129448-A1	06-07-2007	Desai et al.	
	23.	US-2007/0166388-A1	07/19/2007	Desai et al.	
	24.	US-2007/0191473-A1	08/16/2007	Desai et al.	
	25.	US-4,898,735	02-06-1990	Barenholz et al.	
	26.	US-5,318,767-A	06-07-1994	Liversidge et al.	
	27.	US-5,362,478-A	11-08-1994	Desai et al.	
	28.	US-5,415,869-A	05-16-1995	Straubinger et al.	
	29.	US-5,439,686-A	08-08-1995	Desai et al.	
	30.	US-5,498,421-A	03-12-1996	Grinstaff et al.	
	31.	US-5,616,608-A	04-01-1997	Kinsella et al.	
	32.	US-5,650,156-A	07-22-1997	Grinstaff et al.	
	33.	US-5,665,382-A	09-09-1997	Grinstaff et al.	
	34.	US-5,665,383-A	09-09-1997	Grinstaff et al.	
	35.	US-5,670,536-A	09-23-1997	Durr et al.	
	36.	US-5,834,025-A	11-10-1998	De Garavilla et al.	
	37.	US-5,916,596-A	06-29-1999	Desai et al.	
	38.	US-5,997,904-A	12-07-1999	Magdassi et al.	
	39.	US-6,506,405-B1	01-14-2003	Desai et al.	
	40.	US-6,537,579-B1	03-25-2003	Desai et al.	
	41.	US-6,652,884-B2	11-25-2003	Falciani et al.	
	42.	US-6,660,286-B1	12-09-2003	Lambert et al.	
	43.	US-6,727,280-B2	04-27-2004	Palepu et al.	
JDA/	44.	US-6,749,868-B1	06-15-2004	Desai et al.	

FOREIGN PATENT DOCUMENTS			
Examiner	Foreign Patent Document	Publication	Pages, Columns, Lines,
Examiner Signature	/James Anderson/	Date Considered	11/05/2007

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/937,840
				Filing Date	April 21, 2000 (Int'l)
				First Named Inventor	Patrick SOON-SHIONG
				Art Unit	1614
				Examiner Name	J. Anderson
Sheet	2	of	3	Attorney Docket Number	420052000200

Initials*	Cite No. ¹	Country Code ² -Number ³ -Kind Code ⁴ (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
/JDA/	45.	WO-94/18954-A1	09-01-1994	Clover Consolidated Limited		
/JDA/	46.	WO-98/14174-A1	04-09-1998	VivoRx Pharmaceuticals, Inc.		
/JDA/	47.	WO-99/00113-A1	01-07-1999	VivoRx Pharmaceuticals, Inc.		
/JDA/	48.	WO-00/06152-A1	02-10-2000	Novopharm Biotech, Inc.		
/JDA/	49.	WO-00/64437-A1	11-02-2000	American Biosciences, Inc.		
/JDA/	50.	WO-00/71079-A2	11-30-2000	American Bioscience, Inc.		
/JDA/	51.	WO-01/34174-A2,A3	05-17-2001	Entremed, Inc. et al.		
/JDA/	52.	WO-01/89522-A1	11-29-2001	American Bioscience, Inc.		
/JDA/	53.	WO-02/087545-A1	11-07-2002	American Bioscience, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/JDA/	54.	Anonymous. (1994). <u>Drug Facts and Comparisons</u> . Wolters Kluwer: St. Louis, MO, pp. 2780-2785.				
	55.	Chang, A. et al. (1997). "Phase I Study of Weekly One-hour Paclitaxel Treatment in Advanced Malignant Disease," <i>Proc. Am. Soc. Clin. Oncol.</i> 16:232a (Abstract 817), located at < http://www.asco.org/portal/site/ASCO/template.RAW/menuitem.34d60f5624ba07fd506fe3... >, last visited July 3, 2007, 2 pages.				
	56.	Cowens, J.W. et al. (June 15, 1993). "Initial Clinical (Phase I) Trial of TLC D-99 (Doxorubicin Encapsulated in Liposomes)," <i>Cancer Res.</i> 53(12):2796-2802.				
	57.	Gill, P.S. et al. (April 1995). "Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin," <i>J. Clin. Oncol.</i> 13(4):996-1003.				
	58.	Grant, D.S. et al. (March 10, 2003). "Comparison of Antiangiogenic Activities Using Paclitaxel (Taxol) and Docetaxel (Taxotere)," <i>Int. J. Cancer.</i> 104(1):121-129.				
	59.	Kattan, J. et al. (1992). "Phase I Clinical Trial and Pharmacokinetic Evaluation of Doxorubicin Carried by Polyisohexylcyanoacrylate Nanoparticles," <i>Invest. New Drugs</i> 10(3):191-199.				
	60.	Kleinerman, E.S. et al. (1995). "Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma," <i>Am. J. Clin. Oncol.</i> 18(2):93-99.				
	61.	Kolodgie, F.D. et al. (2002). "Sustained Reduction of In-stent Neointimal Growth with the Use of a Novel Systemic Nanoparticle Paclitaxel," <i>Circulation</i> 106:1195-1198.				
	62.	Ng, S.S. et al. (2005). "Metronomic ABI-007 Therapy: Antiangiogenic and Antitumor Activity of a Nanoparticle Albumin-bound Paclitaxel," <i>Proc. Amer. Assoc. Cancer Res.</i> 46 (Abstract #2988), located at < http://www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/702?maxtoshow... >, last visited June 28, 2007, two pages.				
/JDA/	63.	Ng, S.S. et al. (July 2006). "Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-bound Versus Cremophor EL-based Paclitaxel," <i>Clin. Cancer. Res.</i> 12(14):4331-4338.				
	64.	Rote Liste Service GmbH. (1999). <u>Rote Liste 1999</u> , EGV, Aulendorf, Germany, Numbers 76 162 and 06 472, 2 pages.				

Examiner Signature	/James Anderson/	Date Considered	11/05/2007
--------------------	------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/937,840
				Filing Date	April 21, 2000 (Int'l)
				First Named Inventor	Patrick SOON-SHIONG
				Art Unit	1614
				Examiner Name	J. Anderson
Sheet	3	of	3	Attorney Docket Number	420052000200

/JDA/	65.	Schwartz, G.K. et al. (1995). "A Phase II Trial of Doxorubicin HCl Liposome Injection in Patients With Advanced Pancreatic Adenocarcinoma," <i>Invest. New Drugs</i> 13:77-82.	
	66.	Sigma Catalog. (1992). "Biochemicals," pp. 938.	
	67.	Uziely, B. et al. (July 1995). "Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies," <i>J. Clin. Oncol.</i> 13(7):1777-1785.	
	68.	U.S. Patent Application No. 09/446,783 filed May 16, 2000 for Desai et al.	
	69.	U.S. Patent Application No. 11/553,339 filed October 26, 2006 for Desai et al.	
	70.	U.S. Patent Application No. 11/644,850 filed December 22, 2006 for Desai et al.	
	71.	U.S. Patent Application No. 11/880,218, filed July 7, 2007 for Desai et al.	
	72.	U.S. Patent Application No. 11/880,314, filed July 20, 2007 for Desai et al.	
	73.	U.S. Patent Application No. 11/890,819, filed August 7, 2007 for Desai et al.	
	74.	U.S. Patent Application No. 11/833,188, filed August 2, 2007 for Desai et al.	
	75.	U.S. Patent Application No. 11/890,603, filed August 6, 2007 for Desai et al.	
	76.	U.S. Patent Application No. 11/890,197, filed August 3, 2007 for Desai et al.	
	77.	U.S. Patent Application No. 11/890,006, filed August 3, 2007 for Desai et al.	
	78.	U.S. Patent Application No. 11/890,041, filed August 3, 2007 for Desai et al.	
	79.	U.S. Patent Application No. 11/890,639, filed August 6, 2007 for Desai et al.	
↓	80.	U.S. Patent Application No. 11/890,648, filed August 6, 2007 for Desai et al.	
	81.	U.S. Patent Application No. 11/890,599, filed August 6, 2007 for Desai et al.	
/JDA/	82.	U.S. Patent Application No. 11/833,179, filed August 2, 2007 for Desai et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Anderson/	Date Considered	11/05/2007
-----------------------	------------------	--------------------	------------

pa- 1178802